Format

Send to

Choose Destination
Eur Heart J. 2015 Jul 1;36(25):1576-82, 1582a-b. doi: 10.1093/eurheartj/ehv126. Epub 2015 Apr 16.

Redox biomarkers in cardiovascular medicine.

Author information

1
Oxidative Signalling Group, Department of Cardiology, Kolling Institute, University of Sydney, Royal North Shore Hospital, St Leonards, NSW 2065, Australia Department of Cardiology, Royal North Shore Hospital, Sydney, Australia.
2
Cardiovascular Medicine, University of Oxford, Oxford, UK.
3
South Australian Health and Medical Research Institute, University of Adelaide, Adelaide, Australia Department of Cardiology, Royal Adelaide Hospital, Adelaide, Australia.
4
Oxidative Signalling Group, Department of Cardiology, Kolling Institute, University of Sydney, Royal North Shore Hospital, St Leonards, NSW 2065, Australia Department of Cardiology, Royal North Shore Hospital, Sydney, Australia gemma.figtree@sydney.edu.au.

Abstract

The central role of oxidative signalling in cardiovascular pathophysiology positions biometric measures of redox state as excellent markers for research and clinical application. However, despite this tantalizing biological plausibility, no redox biomarker is currently in widespread clinical use. Major recent insights into the mechanistic complexities of redox signalling may yet provide the opportunity to identify markers that most closely reflect the underlying pathobiology. Such redox biomarkers may, in principle, quantify the integrated effects of various known and unknown pathophysiological drivers of cardiovascular disease processes. Recent advances with the greatest potential include assays measuring post-translational oxidative modifications that have significant cellular effects. However, analytical issues, including the relative instability of redox-modified products, remain a major technical obstacle. Appreciation of these challenges may facilitate future development of user-friendly markers with prognostic value in addition to traditional risk factors, and which could be used to guide personalized cardiovascular therapies. We review both established and recently identified biomarkers of redox signalling, and provide a realistic discussion of the many challenges that remain if they are to be incorporated into clinical practice. Despite the current lack of redox biomarkers in clinical application, the integral role of reactive oxygen species in pathogenesis of cardiovascular disease provides a strong incentive for continued efforts.

KEYWORDS:

Biomarker; Cardiovascular disease; Caveolae; Reactive oxygen species; Redox signalling

PMID:
25888005
DOI:
10.1093/eurheartj/ehv126
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center